Incidence of leukopenia after intraperitoneal vs combined intravenous/intraperitoneal chemotherapy in pseudomyxoma peritonei

Table 1 Clinicopathological characteristics of patients with Mitomycin C and oxaliplatin/5-fluorouracil treatment

	MMC	OX/5-FU
No.	32	10
Gender
Male (n = 20; 47%)	15	5
Female (n = 22; 53%)	17	5
Age (yr)	50 ± 14	54 ± 10
Length of operation (h)	09:41 ± 2:27	09:07 ± 1:44
CC-status
CC-0	21	3
CC-1	11	7
PCI	20 ± 11	25 ± 10
Length of hospital stay (d)	22.5 ± 11	16.5 ± 3.5
Resections
Total peritonectomy	30	10
Splenectomy	11	3
Omentectomy	25	3
Cholecystectomy	19	7
Colon	18	3
Small bowel	4	1
Anastomotic insufficiencies	0	0
Leucopenia	10	0
G-CSF treatment	3	0
HAP	2	0
SSI	1	1
PE	2	2
IAA	0	1
UTI	1	0

HAP: Hospital-acquired pneumonia; SSI: Surgical site infections; IAA: Intraabdominal abscess formation; PE: Pleural effusion; UTI: Urinary tract infection; G-CSF: Granulozyte-colony stimulating factor; MMC: Mitomycin C; OX/5-FU: Oxaliplatin/5-fluorouracil.